In: Oncogene, 2021, vol. 40, no. 7, p. 1205–1216
Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens have emerged and have been successfully i mplemented in clinical practice. That said, the stronger inhibition of the AR signaling axis has led in recent years to an increase of prostate cancers that de-differentiate...
|
In: Archives of Gynecology and Obstetrics, 2015, vol. 291, no. 6, p. 1387-1394
|
In: Supportive Care in Cancer, 2015, vol. 23, no. 2, p. 525-545
|
In: Clinical & Experimental Metastasis, 2015, vol. 32, no. 7, p. 677-687
|
In: European Archives of Oto-Rhino-Laryngology, 2015, vol. 272, no. 7, p. 1725-1731
|
In: Annals of Surgical Oncology, 2015, vol. 22, no. 3, p. 931-937
|
In: Supportive Care in Cancer, 2015, vol. 23, no. 2, p. 325-331
|
In: Scientific Reports, 2020, vol. 10, no. 1, p. 7078
Immunotherapies, such as checkpoint blockade of programmed cell death protein-1 (PD-1), have resulted in unprecedented improvements in survival for patients with lung cancer. Nonetheless, not all patients benefit equally and many issues remain unresolved, including the mechanisms of action and the possible effector function of immune cells from non-lymphoid lineages. The purpose of this...
|
In: Cancers, 2020, vol. 12, no. 1, p. 223
Membrane-associated guanylate kinase (MAGUK) with inverted domain structure-1 (MAGI1) is an intracellular adaptor protein that stabilizes epithelial junctions consistent with a tumor suppressive function in several cancers of epithelial origin. Here we report, based on experimental results and human breast cancer (BC) patients’ gene expression data, that MAGI1 is highly expressed and acts...
|
In: Nature communications, 2016, vol. 7, p. 13719
Activation of NOTCH signalling is associated with advanced prostate cancer and treatment resistance in prostate cancer patients. However, the mechanism that drives NOTCH activation in prostate cancer remains still elusive. Moreover, preclinical evidence of the therapeutic efficacy of NOTCH inhibitors in prostate cancer is lacking. Here, we provide evidence that PTEN loss in prostate tumours ...
|